A Selection of Dr. Moghimi's peer-reviewed publications:

  1. Moghimi, S.M., Simberg, D. and Anchordoquy, T.J. (2020) Tuning the engines of nanomedicine. Molecular Therapy 28: 693–694.

  2. Pannuzzo, M., Esposito, S., Wu, L-P., Key, J., Aryal, S., Celia, C., di Marzio, L., Moghimi, S.M. and Decuzzi, P. (2020) Overcoming nanoparticle-mediated complement activation by surface PEG-pairing.  Nano Letters (in press) https://doi.org/10.1021/acs.nanolett0c01011.

  3. Vu, V.P., Gifford, G.B., Chen, F., Benasutti, H., Wang, G., Groman, E.V., Scheinman, R., Saba, L., Moghimi, S.M. and Simberg, D. (2019) Immunoglobulin deposition on biomolecule corona determines complement opsonisation efficiency of preclinical and clinical nanoparticles. Nature Nanotechnology 14: 260–268.

  4. Hall, A., Maynard, S., Wu, L-P., Merchut-Maya, J. M., Strauss, R., Jäättelä, M., Moghimi, S. M. and Bartek, J. (2019) Perturbation of mitochondrial bioenergetics by polycations counteracts resistance to BRAFE600 inhibition in melanoma cells. Journal of Controlled Release 309: 158–172.

  5. Gifford, G., Vu, V.P., Banda, N.K., Holers, V.M., Wang, G., Groman, E., Backos, D., Scheinman, R., Moghimi, S.M. and Simberg, D. (2019) Complement therapeutics meets nanomedicine: overcoming human complement activation and leukocyte uptake of nanomedicines with soluble domains of CD55. Journal of Controlled Release 302: 181–189.

  6. Moghimi, S.M., Simberg, D., Skotland, T., Yaghmur, A. and Hunter, A.C. (2019) The interplay between blood proteins, complement, and macrophages on nanomedicine performance and responses. Journal of Pharmacology and Experimental Therapeutics 370: 581–592.

  7. Moghimi, S.M. and Peer, D. (2019) Reprogramming the lymphocytes axis for advanced immunotherapy. Advanced Drug Delivery Reviews 141: 1–2. 

  8. Rahbarizadeh, F., Ahmadvand, D. and Moghimi, S.M. (2019) CAR T-cell bioengineering: single variable domain of heavy chain antibody targeted CARs. Advanced Drug Delivery Reviews 141: 41–46.

  9. Tavano, R., Gabrielli, L., Lubian, E., Fedeli, C., Visentin, S., De Laureto, P. P., Arrigoni, G., Geffner-smith, A., Chen, F., Simberg, D., Morgese, G., Benetti, E.M., Wu, L., Moghimi, S.M., Mancin, F. and Papini, E. (2018) C1q-mediated complement activation and C3 opsonization trigger recognition of stealth poly(2-methyl-2-oxazoline)-coated silica nanoparticles by human phagocytes. ACS Nano 12: 5834–5847.

  10. Moghimi, S.M. (2018) Nanomedicine safety in preclinical and clinical development: focus on idiosyncratic injection/infusion reactions. Drug Discovery Today 23: 1034–1042.

  11. Moghimi, S.M. and Howard. K.A. (2018) Targeting biological barriers: turning a wall into a therapeutic springboard. Molecular Therapy 26: 933–944.

  12. Griffin, J.I., Wang, G., Smith, W.J., Vu, V.P., Scheinman, R., Stitch, D., Moldovan, R., Moghimi, S. M. and Simberg, D. (2017) Revealing dynamics of accumulation of systemically injected liposomes in the skin by intravital microscopy. ACS Nano 11: 11584–11593.

  13. Wibro, P.P., Anselmo, A. C., Nilsson, P., Sarode, A., Gupta, V., Urbanics, R., Szebeni, J., Hunter, A.C., Mitragotri, S., Mollnes, T.E.  and Moghimi, S.M. (2017) By-passing injection reactions to nanoparticles through shape modification and attachment to erythrocyte. Nature Nanotechnology 12: 589–594.

  14. Ordóñez-Gutiérrez, L., Posado-Fernández, A., Ahmadvand, D., Lettiero, B., Wu, L. P., Antón, M., Flores, O., Moghimi, S. M. and Wandosell, F. (2017) ImmunoPEGliposome-mediated reduction of blood and brain amyloid levels in a mouse model of Alzheimer’s disease is restricted to aged animals. Biomaterials 112: 141–152.

  15. Chen, F., Wang, G., Griffin, J., Brenneman, B., Banda, N. K., Holers, V.M. , Backos, D. S., Wu, L-P., Moghimi, S.M. and Simberg, D. (2017) Complement proteins bind to nanoparticle protein corona and undergo dynamic exchange in vivo. Nature Nanotechnology 12: 387–393.

  16. Anchordoquy, T., Barenholz, Y., Boraschi, D., Chorny, M., Decuzzi, P., Debrovolskaia, M., Farhangrazi, Z.S., Farrell,  D., Gabizon, A., Ghandehari, H.R., Godin, B.,  La-Beck, N.H., Ljubimova, J., Moghimi, S.M., Pagliano, L., Park, J-H., Peer, D., Ruoslahti, E., Serkova, N.J. and D. Simberg (2017) Mechanisms and barriers in anti-cancer nanomedicine: addressing challenges, looking for solutions. ACS Nano 11: 12–18.

  17. Moghimi, S.M. and Simberg, D. (2017) Complement activation turnover on surfaces of nanoparticles. Nano Today 15: 8–10.

  18. Wibroe, P. P., Petersen, S. V., Bovet, N., Laursen, B. W. and Moghimi, S. M. (2016) Soluble and immobilized graphene oxide activates the complement differently dependent on surface oxidation state. Biomaterials 78: 20–126.

  19. Inturi, S., Wang, G., Chen, F., Banda, N. K., Holers, V.M., Moghimi, S.M. and Simberg, D. (2015) Modulatory role of surface coating of superparamagnetic iron oxide nanoworms on complement opsonisation and leukocytes uptake. ACS Nano 9: 10758–10768.

  20. Whitehead, B., Wu, L-P., Hvam, M. L., Aslan, H., Dong, M., Dyrskjøt, L., Ostenfeld, M. S., Moghimi, S. M. and Howard, K. A. (2015). Tumour exosomes display differential mechanical and complement activation properties dependent on malignant state: implications in endothelial leakiness. Journal of Extracellular Vesicles 4: 29685 – http://dx.doi.org/10.3402/jev.v4.29685.

  21. Rahimi Jamnani, F., Shokrgozar, M. A., Ahmadvand, D., Mahboudi, F., Rahbrizadeh, F., Parhamifar, L. and Moghimi, S. M. (2014) T cells expressing VHH-directed oligoclonal chimeric HER2 antigen receptors: towards tumour-directed oligoclonal T cell therapy. Biochimica et Biophysica. Acta – General Subjects 1840: 378–386.

  22. Andersen, A. J., Robinson, J. T., Dai, H., Hunter, A. C., Andresen, T. L. and Moghimi, S. M. (2013) Single-walled carbon nanotube surface control of complement recognition and activation. ACS Nano 7: 1108–1119.

  23. Benjaminsen, R.V., Mattebjerg, M.A., Henriksen, J. R., Moghimi, S.M. and Andresen, T.L. (2013) The possible ‘proton-sponge’ effect of polyethylenimine does not include change in lysosomal pH. Molecular Therapy 21: 147–157.

  24. Brambilla, D., Verpillot, R., Le Droumaguet, B., Nicolas, J., Taverna, M., Kona, J., Lettiero, B., Hashemi, S. H., De Kimpe, L., Canovi, M., Gobbi, M., Nicolas, V., Scheper, W., Moghimi, S.M., Tvaroska, I., Couvreur, P. and Andrieux, K. (2012) PEGylated nanoparticles bind to and alter amyloid-beta peptide conformation: towards engineering of functional nanomedicines for Alzheimer’s disease. ACS Nano 6: 5897–5908.

  25. Moghimi, S.M., Hunter, A.C. and Andresen, T.L. (2012) Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective. Annual Review of Pharmacology and Toxicology 52: 481–503.

  26. Moghimi, S.M., Peer, D. and Langer R. (2011) Re-shaping the future of nanopharmaceuticals: ad iduicium. ACS Nano 5: 8454–8458.

  27. Hamad, I., Al-Hanbali, O., Hunter, A.C., Rutt, K.J., Andresen, T.L. and Moghimi, S. M. (2010) Distinct polymer architecture mediates switching of complement activation pathways at nanosphere-serum interface: implications for stealth nanoparticle engineering. ACS Nano 4: 6629–6638.

  28. Moghimi, S.M. and Hunter, A. C. (2010) Complement monitoring of carbon nanotubes. Nature Nanotechnology 5: 382–382.

  29. Hamad, I., Hunter, A. C., Szebeni, J. and Moghimi, S. M. (2008) Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process. Molecular Immunology 46: 225–232.

  30. Mukhopadhyay, R., Al-Hanbali, O., Pillai, S., Hemmersam, A.G., Meyer, R.L., Hunter, A.C., Rutt, K.J., Besenbacher, F., Moghimi, S.M. and Kingshott, P. (2007) Ordering of binary polymeric nanoparticles on hydrophobic surfaces assembled from low volume fraction dispersions. Journal of the American Chemical Society 129: 13390–13391. 

  31. Moghimi, S.M., Hamad, I., Andresen, T.L., Jorgensen, K. and Szebeni, J. (2006) Methylation of the phosphate oxygen moiety of phospholipid-methoxy(polyethylene glycol) conjugate prevents PEGylated liposome-mediated complement activation and anaphylatoxin production. FASEB Journal 20: 2591–2593. Full-Length Article: https://doi.org/10.1096/fj.06.6186fje 

  32. Moghimi, S. M. (2006) The effect of methoxyPEG chain length and molecular architecture on lymph node targeting of immuno-PEG-liposomes. Biomaterials 27: 136–144.

  33. Moghimi, S.M., Hunter, A.C. and Murray, J.C. (2005) Nanomedicine: current status and future prospects. FASEB Journal 19: 311–330.

  34. Moghimi, S.M., Symonds, P., Murray, J.C., Hunter, A.C., Debska, G. and Szewczyk, A. (2005) A two-stage poly(ethylenimine)-mediated cytotoxicity: implications for gene-transfer/therapy. Molecular Therapy 11: 990–995.

  35. Moghimi, S.M., Hunter, A.C., Murray, J.C. and Szewczyk, A. (2004) Cellular distribution of nonionic micelles. Science 303: 626–627. 

  36. Moghimi, S.M. and Szebeni, J. (2003) Stealth liposomes and nanoparticles: critical issues on protein-binding properties, activation of proteolytic blood cascades and intracellular fate. Progress in Lipid Research 42: 463–478.

  37. Moghimi, S.M., Hunter, A.C. and Murray, J.C. (2001) Long circulating and target-specific nanoparticles: theory to practice. Pharmacological Reviews 53: 283–318.

  38. Moghimi, S. M. (2006) The effect of methoxyPEG chain length and molecular architecture on lymph node targeting of immuno-PEG-liposomes. Biomaterials 27: 136–144.

  39. Moghimi, S. M. and Murray, J. C. (1996) Poloxamer-188 re-visited: a potentially valuable immune modulator? Journal of the National Cancer Institute 88: 766–768.

  40. Moghimi, S. M., Hawley, A. E., Christy, N. M., Gray, T., Illum, L. and Davis, S. S. (1994) Surface engineered nanospheres with enhanced drainage into lymphatics and uptake by macrophages of lymph nodes. FEBS Letters 344: 25–30. 

  41. Porter, C. J. H., Moghimi, S. M., Illum, L., Davis, S. S. (1992) The polyoxyethylene/ polyoxypropylene block co-polymer poloxamer-407 selectively redirects intravenously injected microspheres to sinusoidal endothelial cells of rabbit bone marrow. FEBS Letters 68: 121–126.

July 2017

Dr. Moghimi has written an editorial and also co-edited an issue of Molecular Therapy (Volume 25, Issue 7, July 2017) on the topic of nanoparticle development for gene and cell therapies.

Molecular Therapy:   Volume 25,  Issue 7,  July 5, 2017 

Editorial: Nanoparticle Technology: Having Impact, but Needing Further Optimization

July 2017

Dr. Moghimi's paper published in Molecular Therapy (Volume 25, Issue 7, 1476-1490, July 2017).

Polyplex Evolution: Understanding Biology, Optimizing Performance


Arnaldur Hall,  , Ulrich Lächelt,   Jiri Bartek,  Ernst Wagner,  Seyed Moein Moghimi

April 2017

Dr. Moghimi and colleagues explain Geometry and Particle Hitch-Hiking in this ground-breaking work published in Nature Nanotechnology

Bypassing adverse injection reactions to nanoparticles through shape modification and attachment to erythrocytes

Peter Popp Wibroe, Aaron C. Anselmo,, Per H. Nilsson, Apoorva Sarode, Vivek Gupta, Rudolf Urbanics, Janos Szebeni,  Alan Christy Hunter, Samir Mitragotri, Tom Eirik Mollnes & Seyed Moein Moghimi

March 2017

Dr. Moghimi and Colleagues publish work on the role protein corona on complement activation in Nature Nanotechnology

Complement proteins bind to nanoparticle protein corona and undergo dynamic exchange in vivo

Fangfang Chen, Guankui Wang, James I. Griffin, Barbara Brenneman, Nirmal K. Banda, V. Michael Holers, Donald S. Backos, LinPing Wu, Seyed Moein Moghimi & Dmitri Simberg

Copyright © 2020 by  S M Discovery Group. All rights reserved.